Extended Data Fig. 6: On-chip measurement of CAR-T killing efficacy and synapse formation and CD19-directed therapy challenge ex vivo. | Nature Immunology

Extended Data Fig. 6: On-chip measurement of CAR-T killing efficacy and synapse formation and CD19-directed therapy challenge ex vivo.

From: NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia

Extended Data Fig. 6

(a) The experimental workflow of on-chip measurement of CAR-T killing efficacy and synapse formation capability using a 3D microfluidic HUVEC vascularized model. (b) On-chip measurement of the frequency of synapse formation between T-cells and sgRNA-expressing BCP-ALL (independent experiments with n = 4, unpaired two-sided t-test, mean and standard error shown, error bars represent s.e.m). (c-d) Representative flow cytometry of (c) blinatumomab and (d) TRAC CD19 CAR treatment following 24 hours of co-culture with sgRNA-expressing (mCherry+) BCP-ALL. Countbright beads indicated by APC-Cy7.

Source data

Back to article page